Oxytocin vs SS-31

Oxytocin

Oxytocin is a cyclic nonapeptide hormone (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2) with an internal disulfide bridge, naturally produced in the hypothalamic paraventricular and supraoptic nuclei and released from the posterior pituitary. It acts through the oxytocin receptor (OXTR), a G-protein coupled receptor expressed in the brain, uterus, mammary glands, cardiovascular tissue, and immune cells. Centrally, oxytocin modulates social bonding, trust, empathy, and anxiety through interactions with dopaminergic reward circuits and amygdala inhibition. Research by Kosfeld et al. (2005) published in Nature demonstrated that intranasal oxytocin use increased trust behavior in human economic game paradigms, a landmark finding in social neuroscience. Studies in Biological Psychiatry by Hollander et al. showed that oxytocin improved emotion recognition and social cognition in autism spectrum models. Preclinical research published in Psychoneuroendocrinology indicated that oxytocin reduced cortisol responses and amygdala activation during stress exposure, suggesting anxiolytic properties mediated through limbic circuit modulation. Compared to vasopressin (ADH), which shares structural similarity differing by only two amino acids, oxytocin produces distinct behavioral and physiological effects. Vasopressin tends toward aggression and vigilance modulation, while oxytocin promotes prosocial behavior. Synthetic oxytocin analogues like carbetocin offer longer half-lives but altered receptor selectivity profiles. Oxytocin requires careful storage at -20°C in lyophilized form, as it is sensitive to oxidation and degradation. Reconstitute with bacteriostatic water and store at 2-8°C, using within 2-3 weeks due to its relatively fragile disulfide bond. This peptide is widely studied by social neuroscientists, psychiatrists researching autism and anxiety disorders, and reproductive biologists.

SS-31

SS-31, also known as Elamipretide or Bendavia (D-Arg-Dmt-Lys-Phe-NH2), is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Its primary mechanism involves binding to cardiolipin, a phospholipid unique to mitochondrial membranes that is essential for electron transport chain organization and ATP synthase function. By stabilizing cardiolipin microdomains, SS-31 modulates electron transfer between complexes III and IV, reduces electron leak, and limits reactive oxygen species (ROS) generation at the source. Research by Szeto (2006) published in AAPS Journal described SS-31's unique mitochondria-targeting pharmacology, demonstrating 5,000-fold concentration in mitochondria relative to cytoplasm within minutes of exposure. Clinical studies published in Circulation: Heart Failure by Daubert et al. showed that SS-31 improved left ventricular volumes in heart failure patients during a Phase 1/2 trial. Preclinical work in the Journal of the American Society of Nephrology demonstrated renal protective effects in ischemia-reperfusion injury models, with SS-31 preserving mitochondrial cristae structure and reducing tubular cell death. Compared to general antioxidants like CoQ10 or vitamin E, SS-31 targets ROS production at the mitochondrial source rather than scavenging free radicals after they are formed. This upstream approach is considered more efficient by researchers. MitoQ, another mitochondria-targeted compound, accumulates via membrane potential rather than cardiolipin binding, giving SS-31 a distinct pharmacological profile, particularly in depolarized or damaged mitochondria. Store lyophilized SS-31 at -20°C in a desiccated, light-protected environment. Reconstitute with bacteriostatic water and store at 2-8°C, using within 4 weeks. SS-31 is actively investigated by mitochondrial biologists, cardiologists studying heart failure, nephrologists, and aging researchers examining mitochondrial dysfunction as a driver of age-related disease.

Frequently Asked Questions